GLP-1s could help curb substance use disorders, from alcohol to opioids, study suggests – NBC News

GLP-1 Drugs and Their Potential Impact on Substance Use Disorders: A Report Emphasizing Sustainable Development Goals

Introduction

Emerging evidence suggests that GLP-1 drugs, including semaglutide and tirzepatide, may assist individuals in reducing cigarette smoking, alcohol consumption, and opioid use. This development aligns with the Sustainable Development Goals (SDGs), particularly SDG 3: Good Health and Well-being, by addressing substance use disorders (SUDs) and promoting healthier lives.

Background and Research Overview

As GLP-1 medications have gained popularity, anecdotal reports indicated diminished urges to consume alcohol or drugs among users. Subsequent peer-reviewed studies have supported these observations.

Christian Hendershot, Director of Clinical Research at the USC Institute for Addiction Science, emphasized the accumulating positive potential of GLP-1s in treating substance use.

Recent Study and Methodology

1. A recent study published in The BMJ expanded the scope to include multiple substance use disorders such as cannabis, cocaine, nicotine, and opioids.
2. Researchers analyzed records from over 600,000 patients within the Department of Veterans Affairs database, predominantly male (90%) with an average age of 65.
3. All patients had Type 2 diabetes and were treated either with GLP-1 drugs or sodium-glucose cotransporter-2 inhibitors (SGLT2).
4. The study employed emulated target trials to simulate seven clinical trials, assessing both treatment effects and prevention potential of GLP-1 drugs on substance use disorders.

Key Findings

• Among individuals with pre-existing substance use disorders, GLP-1 drug users experienced fewer emergency room visits, hospitalizations, and deaths related to substance use.
• The positive effects were consistent across various substances, including alcohol, opioids, and stimulants.
• GLP-1 drugs may address the root causes of addiction, suggesting a broad-spectrum therapeutic potential.
• Preliminary evidence indicated that GLP-1 drugs might also help prevent the development or recurrence of substance use disorders.

Implications for Sustainable Development Goals

This research supports several SDGs, notably:

• SDG 3 (Good Health and Well-being): By potentially providing effective treatment and prevention for multiple substance use disorders, GLP-1 drugs contribute to reducing premature mortality and promoting mental health.
• SDG 10 (Reduced Inequalities): Addressing substance use disorders in diverse populations, including veterans and older adults, helps reduce health disparities.
• SDG 17 (Partnerships for the Goals): The study exemplifies collaboration between research institutions and healthcare systems to advance public health knowledge.

Challenges and Future Directions

• Substance use disorders affect approximately 50 million people in the United States, yet treatment access remains limited.
• Current FDA-approved medications target alcohol, opioid, and nicotine use disorders, but effective treatments for cannabis, stimulants, and sedatives are lacking.
• Relapse rates remain high even with existing treatments, highlighting the need for novel therapies.
• Further randomized clinical trials are underway to rigorously test GLP-1 drugs’ efficacy in treating addiction.
• Researchers acknowledge that substance use disorders are complex, and no single medication will be universally effective.

Mechanism of Action

GLP-1 drugs are believed to modulate the brain’s reward signaling pathways. Analogous to their effect in obesity treatment—where they reduce the constant preoccupation with food—these drugs may similarly diminish cravings and preoccupation with addictive substances.

Conclusion

The growing body of evidence positions GLP-1 drugs as promising candidates for addressing multiple substance use disorders, contributing to the achievement of SDG 3 by improving health outcomes and reducing the burden of addiction. Continued research and clinical trials will clarify their role in comprehensive addiction treatment strategies.

1. Sustainable Development Goals (SDGs) Addressed or Connected

1. SDG 3: Good Health and Well-being
   • The article discusses advances in medical treatment for substance use disorders, which directly relates to improving health and well-being.
   • Focus on reducing substance abuse and related health complications.
2. SDG 10: Reduced Inequalities
   • Substance use disorders affect diverse populations, including veterans and older adults, highlighting the need to reduce health inequalities.

2. Specific Targets Under Those SDGs Identified

1. SDG 3 Targets
   • Target 3.5: Strengthen the prevention and treatment of substance abuse, including narcotic drug abuse and harmful use of alcohol.
   • Target 3.4: Reduce premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.
2. SDG 10 Targets
   • Target 10.2: Empower and promote the social, economic and political inclusion of all, irrespective of age, sex, disability, race, ethnicity, origin, religion or economic or other status.

3. Indicators Mentioned or Implied to Measure Progress

1. Indicators Related to SDG 3.5
   • Number of emergency room visits related to substance use.
   • Number of hospitalizations related to substance use disorders.
   • Mortality rates related to substance use.
   • Prevalence of substance use disorders in populations (e.g., veterans, older adults).
   • Rates of relapse and treatment success for substance use disorders.
2. Indicators Related to SDG 10.2
   • Access to treatment for substance use disorders across different demographic groups.
   • Inclusion of marginalized populations in health interventions.

4. Table of SDGs, Targets, and Indicators

Source: nbcnews.com